Related Experiment Video
Updated: Oct 1, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Management of stage III and IVa uterine cancer
Camilla Nero1,2, Francesca Tronconi3, Elena Giudice2
1Department of Woman, Child and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio, Italy.
Abstract:
The prognosis of patients with advanced endometrial cancer is poor with limited therapeutic options. Nevertheless, the integration of molecular features in the clinico-pathological classification of endometrial cancer has significantly refined prognostic risk groups, representing a major breakthrough not only in the management of the disease but also in treatment perspectives. New therapeutic compounds such as target therapies, immunotherapy, and hormonal therapies have emerged for this clinical setting. Furthermore, molecular-driven clinical trials may improve significantly the efficacy of new treatments selecting those patients who are highly likely to respond. This review aims at describing the state of the art of advanced stage III-IVa endometrial cancer management, providing also the most interesting clinical perspectives.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi VI: Surgical Management
Mitral Valve Prolapse III: Nursing Management
Mitral Stenosis III: Medical Management
Treatment Resistant Cancers
Venous Thrombosis III: Interprofessional Care

